Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 11;18(1):e1003454. doi: 10.1371/journal.pmed.1003454

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Jackson et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 2 — (A) Progression-free survival for KRdc compared to the Tdc/Rdc control group. (B) Subgroup analysis of progression-free survival with KRdc compared to the Tdc/Rdc control group. *Performed only for patients with subgroup data available. (C) Progression-free survival for KRdc compared to the Tdc and Rdc groups separately. HiR, high risk; ISS, International Staging System; KRdc, carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide; NE, not estimable; P. (het), p-value from likelihood ratio test for heterogeneity of effect; Rdc, lenalidomide, dexamethasone, and cyclophosphamide; SR, standard risk; Tdc, thalidomide, dexamethasone, and cyclophosphamide; UHiR, ultra-high risk.